Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide (Gilead Sciences)
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide** is a fixed-dose, four-drug oral antiretroviral regimen marketed as **Genvoya** by Gilead Sciences. Elvitegravir is an HIV-1 integrase strand transfer inhibitor that blocks proviral DNA integration; emtricitabine and tenofovir alafenamide are nucleoside/nucleotide reverse transcriptase inhibitors whose active intracellular metabolites inhibit HIV-1 reverse transcriptase and terminate viral DNA synthesis. Cobicistat is a CYP3A inhibitor included as a pharmacokinetic booster to increase elvitegravir exposure. It is approved as a complete regimen for treatment of HIV-1 infection in treatment-naive adults and pediatric patients weighing at least 25 kg, and for eligible virologically suppressed patients switching from a stable regimen. ([gilead.com](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/genvoya/genvoya_pi.pdf))
- Brand names
- Genvoya
- Other names
- E/C/F/TAFEVG/COBI/FTC/TAFelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
02
Targets
ABCG2 (Breast cancer resistance protein)Integrase allosteric pocket (HIV)Human immunodeficiency virus type 1 reverse transcriptaseHIV-2 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)ABCB1 (P-glycoprotein)CYP2C19 (Cytochrome P450 2C19)CYP3A4 (Cytochrome P450 3A4)CYP3A5 (Cytochrome P450 family 3 subfamily A member 5)RAG1 (Recombination Activating Gene 1)
Beyond the preview
Go deeper on elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide (Gilead Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide (Gilead Sciences).